Stéphane Bancel, Moderna CEO (AP Images)

Mod­er­na posts a promis­ing snap­shot of hu­man da­ta for a lead­ing Covid-19 vac­cine — and ral­ly makes Bob Langer a bil­lion­aire

Mod­er­na $MR­NA just post­ed some of the most ea­ger­ly an­tic­i­pat­ed hu­man da­ta for a vac­cine in mod­ern his­to­ry. And it’s pos­i­tive.

The bot­tom line: Mod­er­na’s mR­NA-1273 trig­gered a ther­a­peu­tic im­mune re­sponse in 8 pa­tients at the low and mid-dose — 25 μg and 100 μg af­ter a sin­gle in­jec­tion. There were dose-de­pen­dent in­creas­es in im­muno­genic­i­ty through both dos­es cov­er­ing 4 pa­tients in each group, ac­cord­ing to Mod­er­na, with pa­tients achiev­ing the same or bet­ter lev­el of re­sponse seen in re­cov­er­ing pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.